Taysha Gene Therapies (TSHA) Current Leases (2022 - 2026)
Taysha Gene Therapies (TSHA) posted Current Leases of $1.8 million for Q1 2026, down 2.2% sequentially from $1.9 million in Q4 2025, and up 0.88% YoY from $1.8 million in Q1 2025.
Taysha Gene Therapies (TSHA) Current Leases (2022 - 2026) Analysis & Trends
Taysha Gene Therapies has reported Current Leases for 5 years, with the latest figure at $1.8 million in Q1 2026.
- Quarterly Current Leases rose 0.88% year-over-year to $1.8 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $1.8 million (up 0.88% YoY) and the FY2025 annual result came in at $1.9 million, down 0.64% from the prior year.
- Current Leases slipped to $1.8 million in Q1 2026 per TSHA's latest filing, from $1.9 million in the prior quarter.
- Over five years, Current Leases peaked at $1.9 million in Q4 2024 and troughed at $1.5 million in Q4 2022.
- A 5-year average of $1.7 million and a median of $1.7 million in 2023 frame the typical range for Current Leases.
- The sharpest annual moves came in 2024 and 2025: Current Leases increased 18.01% in 2024, then slipped 8.1% in 2025.
- Over 5 years, Current Leases stood at $1.5 million in 2022, then grew by 8.22% to $1.6 million in 2023, then gained by 14.03% to $1.9 million in 2024, then dropped by 0.64% to $1.9 million in 2025, then declined by 2.2% to $1.8 million in 2026.
- According to Business Quant data, Current Leases over the past three periods registered $1.8 million, $1.9 million, and $1.7 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Current Leases (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 720.00 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 11.00 Mn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 16.75 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 21.95 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 2.24 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 45.93 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 6.27 Mn |
| 10 | Taysha Gene Therapies | 1.94 Bn | 1.94 Bn | - | 1.16 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 1.16 Mn |
| Mar 31, 2026 | 1.82 Mn |
| Dec 31, 2025 | 1.87 Mn |
| Sep 30, 2025 | 1.67 Mn |
| Jun 30, 2025 | 1.74 Mn |
| Mar 31, 2025 | 1.81 Mn |
| Dec 31, 2024 | 1.88 Mn |
| Sep 30, 2024 | 1.82 Mn |
| Jun 30, 2024 | 1.75 Mn |
| Mar 31, 2024 | 1.70 Mn |
| Dec 31, 2023 | 1.65 Mn |
| Sep 30, 2023 | 1.54 Mn |
| Jun 30, 2023 | 1.64 Mn |
| Mar 31, 2023 | 1.75 Mn |
| Dec 31, 2022 | 1.52 Mn |